ADC Therapeutics (ADCT) CFO reports 53,236-share tax withholding from RSU vesting

Rhea-AI Filing Summary

ADC Therapeutics SA's Chief Financial Officer, Jose Carmona, reported a routine share withholding related to equity compensation. On 12/06/2025, the company withheld 53,236 common shares to cover his tax obligations arising from the vesting of previously granted restricted share units. The shares were valued at $3.29 per share for this tax withholding event.

After this transaction, Carmona beneficially owned 488,656 common shares, held directly. The filing is a standard Form 4 disclosure of insider equity activity rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Carmona Jose

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Shares	53,236	$3.29	$175K

Holdings After Transaction: Common Shares — 488,656 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carmona Jose

(Last) (First) (Middle)

430 MOUNTAIN AVENUE, SUITE 404

(Street)

NEW PROVIDENCE NJ 07974

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/06/2025		F(1)		53,236	D(1)	$3.29	488,656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, Attorney-in-Fact for Jose Carmona	12/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADC Therapeutics (ADCT) disclose in this Form 4?

The filing reports that Chief Financial Officer Jose Carmona had 53,236 common shares withheld by ADC Therapeutics to satisfy tax withholding obligations from the vesting of restricted share units.

Was the ADCT insider transaction an open-market buy or sell?

No. The 53,236 ADCT shares were withheld by the issuer for taxes tied to vesting restricted share units, not bought or sold in the open market.

At what price were the ADC Therapeutics shares valued for the tax withholding?

The 53,236 common shares withheld for tax purposes were valued at $3.29 per share in the reported transaction.

How many ADC Therapeutics (ADCT) shares does the CFO own after this transaction?

Following the tax withholding transaction, CFO Jose Carmona beneficially owned 488,656 common shares of ADC Therapeutics, held directly.

What role does the reporting person hold at ADC Therapeutics (ADCT)?

The reporting person, Jose Carmona, is an officer of ADC Therapeutics SA, serving as the company’s Chief Financial Officer.

What is the transaction code used in the ADCT Form 4 filing?

The transaction is coded as “F”, which indicates shares withheld to pay tax obligations in connection with equity award vesting.